Clinical implications of genomic driver alterations in hormone receptor-positive, human epidermal growth factor receptor (HER) 2-negative early breast cancer
Year: 2021
Type: dissertation
Abstract: Global initiatives applying next generation sequencing to thousands of primary and metastatic tumour samples have detailed the genomic landscape of breast cancer.These unique insights have transformed our understanding of the biological processes underlying these tumours.Despite this, the clinical relevance of these findings remains poorly understood.This is because these datasets are frequently heterogeneous, include patients that may not have received contemporary treatments, often have limited clinical annotation, and commonly lack long-term follow-up for patient survival outcomes.In order to better assess the clinical relevance of genomic driver alterations in breast cancer, this research project performed genomic sequencing using primary tumour samples from patients enrolled in two pivotal phase 3 clinical trials -the Breast International Group 1-98 (BIG 1-98) study and the Suppression of Ovarian Function Trial (SOFT).This provided a well-defined population with hormone receptorpositive, human epidermal growth factor receptor (HER) 2-negative (HR+HER2-) early breast cancer in both postmenopausal and premenopausal populations, as well as long-term survival outcome data collection.Crucially, this allowed for further investigation of late distant recurrence, a unique feature of HR+HER2-breast cancers, as well as the ability to focus on distinct high-risk subpopulations, such as breast cancer arising in young women.In the postmenopausal BIG 1-98 study, comprehensive panel sequencing was performed using 538 tumour samples from patients with HR+HER2-early breast cancer.PIK3CA mutations were the most common driver (49%) and were associated with a reduction in the risk of distant recurrence.Contrastingly, TP53 mutations, amplifications on 11q13 and 8p11, and increasing number of driver alterations were associated with an increase in the risk of distant recurrence.Additionally, PIK3CA mutations were predictive of a greater magnitude of benefit from letrozole compared with tamoxifen.Using the same dataset, we further investigated the Chapter 1 references 1 Global Burden of Disease Cancer, C. et al.The Global Burden of Cancer 2013.
Author: Luen, Stephen James
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Funders: Breast Cancer Research Foundation, Bristol-Myers Squibb, Pfizer, AstraZeneca, Les Laboratories Pierre Fabre, Puma Biotechnology, National Breast Cancer Foundation, Cancerfonden, Oncosuisse, Vetenskapsrådet, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, Ipsen, Genentech, Foundation Medicine, National Health and Medical Research Council, Cancer Council Victoria, National Cancer Institute, Daiichi Sankyo Europe
OpenAlex ID: W6989890740
